These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33734140)

  • 1. Encephalitis Induced by Durvalumab During Treatment of Metastatic Small-Cell Lung Cancer: Illustrative Case and Review of the Literature.
    Shechtman Y; Shalata W; Khoury R; Mahajna A; Weller B; Agbarya A
    J Immunother; 2021 Sep; 44(7):243-247. PubMed ID: 33734140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab-induced Limbic Encephalitis with Anti-Hu Antibody in a Patient With Advanced Pleomorphic Carcinoma of the Lung.
    Matsuoka H; Kimura H; Koba H; Tambo Y; Ohkura N; Hara J; Sone T; Kasahara K
    Clin Lung Cancer; 2018 Sep; 19(5):e597-e599. PubMed ID: 29857970
    [No Abstract]   [Full Text] [Related]  

  • 3. Case Report: Limbic encephalitis following treatment with durvalumab for small-cell lung cancer.
    Moss TT; Stavem K; Aandahl A; Gløersen AS; Grønberg BH; Neumann K; Vedeler CA; Lundqvist C
    Front Immunol; 2023; 14():1278761. PubMed ID: 37908347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Hu-Associated Autoimmune Limbic Encephalitis in a Patient with PD-1 Inhibitor-Responsive Myxoid Chondrosarcoma.
    Papadopoulos KP; Romero RS; Gonzalez G; Dix JE; Lowy I; Fury M
    Oncologist; 2018 Jan; 23(1):118-120. PubMed ID: 29158368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
    Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paraneoplastic limbic encephalitis associated with lung cancer.
    Shen K; Xu Y; Guan H; Zhong W; Chen M; Zhao J; Li L; Wang M
    Sci Rep; 2018 May; 8(1):6792. PubMed ID: 29717222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer.
    Wang L; Lou H; Li B; Li J; Yang YM
    Invest New Drugs; 2022 Feb; 40(1):151-156. PubMed ID: 34287773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
    Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
    JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
    Chen J; Wang J; Xu H
    Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab.
    Nakashima K; Demura Y; Oi M; Tabata M; Tada T; Shiozaki K; Akai M; Ishizuka T
    Intern Med; 2020 Dec; 59(23):3055-3059. PubMed ID: 32727989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
    Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
    Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer.
    Shibata Y; Murakami S
    Expert Opin Drug Saf; 2020 Jun; 19(6):653-659. PubMed ID: 32357806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial.
    Kuon J; Hommertgen A; Krisam J; Lasitschka F; Stenzinger A; Blasi M; Bozorgmehr F; Maenz M; Kieser M; Schneider M; Thomas M
    Trials; 2020 Apr; 21(1):352. PubMed ID: 32321565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study.
    Thomas A; Vilimas R; Trindade C; Erwin-Cohen R; Roper N; Xi L; Krishnasamy V; Levy E; Mammen A; Nichols S; Chen Y; Velcheti V; Yin F; Szabo E; Pommier Y; Steinberg SM; Trepel JB; Raffeld M; Young HA; Khan J; Hewitt S; Lee JM
    J Thorac Oncol; 2019 Aug; 14(8):1447-1457. PubMed ID: 31063862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
    Senan S; Okamoto I; Lee GW; Chen Y; Niho S; Mak G; Yao W; Shire N; Jiang H; Cho BC
    Clin Lung Cancer; 2020 Mar; 21(2):e84-e88. PubMed ID: 31948903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of 18F-FDG PET/CT in management of paraneoplastic limbic encephalitis combined with small cell lung cancer: A case report.
    Castagnoli H; Manni C; Marchesani F; Rossi G; Fattori S; Capoccetti F
    Medicine (Baltimore); 2019 Aug; 98(35):e16593. PubMed ID: 31464894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of small-cell lung cancer associated with paraneoplastic limbic encephalitis during chemotherapy].
    Isobe K; Nagata R; Ota H; Sugino K; Shibuya K; Homma S
    Nihon Kokyuki Gakkai Zasshi; 2011 Aug; 49(8):602-6. PubMed ID: 21894777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer.
    Nakamura M; Otsuka T; Hayashi R; Horita T; Ota M; Sakurai N; Takano H; Hayashi T; Kumagai M; Yamada S; Arisawa T
    Intern Med; 2020 Nov; 59(21):2711-2717. PubMed ID: 32669493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.